**Core tip:** Although metabolic imaging is increasingly utilized in prostate cancer (PCa), the mechanisms leading to cancer-related metabolic rearrangements and consequent imaging findings remain poorly understood. This study compared two modalities utilizing distinct metabolic pathways, proton magnetic resonance spectroscopic imaging (^1^H-MRSI) and ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG-PET/CT), in local PCa. Abnormal intermediary metabolism on ^1^H-MRSI was present in 21/22 patients, while abnormal glycolysis on ^18^F-FDG-PET/CT was detected in only 3/22 patients. This study provides an insight why metabolic PET agents promising for detection of PCa target intermediary metabolism. On the other hand, elevated glycolysis may have ominous prognostic implications in PCa.

INTRODUCTION
============

Multimodality imaging is performed in patients with cancer to understand metabolism, however the mechanisms leading to metabolic rearrangements remains poorly understood. By decoding the connections between cancer signaling and metabolism, it may be possible to better understand the clinical implications of imaging findings and develop new imaging strategies.

In patients with prostate cancer (PCa), two key functional imaging modalities, proton magnetic resonance spectroscopic imaging (^1^H-MRSI) and ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG-PET/CT), are used to identify cancer-induced changes in cellular metabolism\[[@B1]-[@B3]\]. On ^1^H-MRSI, decreased levels of citrate (a Krebs cycle and fatty acid synthesis intermediate) and polyamines (amino acid metabolism intermediates) and elevated choline (a precursor of membrane synthesis) are a signature of PCa\[[@B2],[@B4]-[@B7]\]. On ^18^F-FDG-PET, increased glucose uptake by glucose transporters and glucose phosphorylation to glucose-6-phosphate by hexokinase are used for identifying PCa and other cancers\[[@B3],[@B8]\]. The indications for ^1^H-MRSI and ^18^F-FDG-PET/CT examinations in patients with PCa are very different\[[@B9],[@B10]\]. ^1^H-MRSI adds incremental value to standard prostate magnetic resonance imaging (MRI) in the detection of primary or recurrent loco-regional PCa and in the evaluation of its aggressiveness (Gleason Grade)\[[@B9]-[@B14]\]. ^1^H-MRSI can also be used prior to treatment to predict biochemical relapse of PCa after radical prostatectomy or the presence of insignificant PCa\[[@B14]-[@B17]\]. In contrast, ^18^F-FDG-PET/CT is not recommended for the detection and initial evaluation of PCa or detection of early recurrence. Various other PET agents, such as ^18^F- or ^11^C-labeled choline or acetate, several various amino acids, and agents binding to the transmembrane PSMA molecule are available for this purpose\[[@B18]-[@B24]\]. ^18^F-FDG plays a role in the characterization of advanced metastatic PCa\[[@B8],[@B25]\]. The clinical significance of the current study lies in exploring the use of multimodality imaging in local PCa. In this study, we wanted to explore the relationship using multimodality imaging between concentrations of intermediary metabolites citrate and choline, measured by ^1^H-MRSI, and glycolysis as noted on ^18^F-FDG PET/CT in local PCa.

MATERIALS AND METHODS
=====================

Patient demographics
--------------------

Our study was compliant with the Health Insurance Portability and Accountability Act. Patient data were collected and handled in accordance with institutional and federal guidelines. Twenty-two patients who were referred from the Urology department for endorectal MRI/MRSI examinations (April 2002 to July 2007) and ^18^F-FDG-PET/CT and then underwent prostatectomy as primary or salvage treatment were included in the study. Whole-mount step-section pathology of the surgical specimen was available for all the patients. Of the 22 patients, 11 were imaged before treatment while 11 were imaged after external beam radiation therapy. The institutional review board approved our retrospective review of multimodality imaging using MRI/MRSI and ^18^F-FDG-PET/CT studies, pathology data (from surgical pathology), and clinical follow-up data and waived the informed consent requirement. The mean time between the MRSI and PET exams was 11 ± 37 d (± SD).

Endorectal MRI/MRSI data acquisition and processing
---------------------------------------------------

Data were acquired on a 1.5-Tesla GE Signa Horizon scanner. MRI was done using a pelvic phased-array coil and an expandable endorectal coil; T1- and T2-weighted spin-echo MR images were obtained using a previously described standard prostate imaging protocol (total time, approximately 30 min)\[[@B4]\]. MR image acquisition was followed by a standard MRSI protocol with point-resolved spectroscopic voxel excitation and water and lipid suppression (total time, 17 min) in a voxel array and the SI dimension zero filled to 16 slices (3-mm resolution) with a voxel size of 0.12 to 0.16 cm^3\[4\]^. MRSI data were overlaid on the corresponding T2-weighted images, including the raw spectra and the metabolic ratio \[choline + creatine to citrate (CC/C)\]\[[@B4]\]. Tumors were identified by dedicated radiologists with \> 5 years of experience in prostate imaging.

^1^H-MRSI data interpretation
-----------------------------

An MRI physicist with \> 10 years of experience in prostate MRSI retrospectively interpreted the ^1^H-MRSI studies using established metabolic criteria for the evaluation of PCa in the peripheral and transition zones\[[@B6],[@B14],[@B26],[@B27]\]. The physicist, who was blinded to clinical data and surgical pathology, recorded the location and total number of suspicious voxels (tumor volume estimation), maximum (max) CC/C, and mean CC/C for the index lesion\[[@B6],[@B14],[@B26],[@B27]\].

^18^F-FDG-PET/CT data acquisition and processing
------------------------------------------------

Details of the 18F-FDG-PET/CT imaging procedure have been described previously\[[@B28]\]. Briefly, a low-dose CT scan (120-140 kV, approximately 80 mA), which is used for attenuation correction of PET emission images as well as for anatomic localization of PET abnormalities, was acquired first. This was followed by acquisition of PET emission images of the lower pelvis including of the prostate for 5 min per bed position. Images were reconstructed using iterative algorithms with average slice thickness of 3 mm and a 128 × 128 matrix size. Patients were scanned in the supine position. Before the examination, patients fasted for at least 6 h, but liberal intake of water was allowed. Patients were injected intravenously with 444-555 MBq of ^18^F-FDG and a PET/CT scan started after an uptake period of approximately 60 min. Plasma glucose level was \< 200 mg at the time of imaging in all patients.

^18^F-FDG-PET/CT data interpretation
------------------------------------

All ^18^F-FDG-PET/CT data were available for retrospective review on a standard clinical workstation (PACS with Advance Work Station extension; General Electric). One board-certified radiologist/nuclear medicine physician, who had \> 10 years of experience in PET and \> 5 years of experience in prostate imaging, reviewed the ^18^F-FDG-PET/CT studies. PET images were analyzed in three orthogonal planes (transaxial, coronal, sagittal) both visually and quantitatively. For quantitative PET analysis, maximum standardized uptake value (SUVmax) and average SUV (SUVmean) of the index lesion were determined using a Volume of Interest with 40% threshold of SUVmax. All SUVs were normalized to body weight.

Pathology
---------

Whole-mount transverse serial sections of the prostate were prepared as described previously\[[@B29]\]. The distal 5-mm portion of the apex was amputated and coned. The remainder of the gland was serially sectioned from the apex to the base at 3-4-mm intervals and submitted in its entirety for paraffin-embedded whole mounts. Cancer foci were outlined in ink on whole-mount, apical, and seminal vesicle sections and photographed. The photographs constituted the tumor maps. The primary and secondary Gleason grades as well as the pathologic tumor node stage were also determined. The index lesion was identified in all cases as the tumor with the largest volume. Tissue sections stained with H and E were examined by one uro-pathologist blinded to imaging and clinical data.

Matching of MRI/MRSI data, ^18^F-FDG-PET/CT and pathology data
--------------------------------------------------------------

The matching of imaging and pathology for the index lesion was performed in consensus by two dually-boarded radiologists/nuclear medicine physicians with \> 5 years and \> 15 years of experience in prostate imaging. The histopathologic axial step sections were visually matched with corresponding axial T2-weighted transverse MR images with superimposed MRSI data and fused ^18^F-FDG PET/CT data with a precision of ± 1 slice based on established anatomic landmarks\[[@B12]\]. Because the spectroscopic data were acquired in the same position and with the same gradients as the imaging data, registration of the spectroscopic data with the T2-weighted images was automatic, and the spectroscopic data could be compared with the most closely corresponding histopathologic step section.

Statistical analysis
--------------------

Clinical and pathological characteristics were described using medians and ranges for continuous variables and frequencies and percents or proportions for categorical variables. Gleason grades were summed into Gleason scores of 6, 7, 8 or 9.

The localization rates of ^18^F-FDG-PET/CT and ^1^H-MRSI were calculated along with exact 95% confidence intervals. The relationships between PET parameters (SUVmax and SUVmean) and MRSI parameters (CC/Cmax, CC/Cmean, Total \# Voxels) were assessed using Spearman's rank correlation and graphically displayed with scatter plots and 95% confidence bands. Additionally, the relationships of PET and MRSI parameters to surgical Gleason score were assessed with Spearman's rank correlation and, given the Gleason score's ordinal nature, graphically illustrated with box plots. *P*-values less than 0.05 were considered statistically significant. All analyses were done using SAS 9.4 (The SAS Institute, Cary, NC).

RESULTS
=======

Patient characteristics are summarized in Table [1](#T1){ref-type="table"}. The patients had a median age of 58 years (range: 47-70 years) and median PSA of 4.81 ng/mL (range: 0.11-96.53 ng/mL).

###### 

Patient characteristics

                                                   ***n* (%)**                                  
  ------------------------------------------------ -------------------------------------------- -----------
  Clinical stage[1](#T1FN1){ref-type="table-fn"}   T1c                                          10 (45.5)
                                                   T2a                                          4 (18.2)
                                                   T2b                                          4 (18.2)
                                                   T2c                                          1 (4.5)
                                                   T3                                           1 (4.5)
                                                   T3a                                          2 (9.1)
  Biopsy Gleason score                             0 + 0                                        1 (4.5)
                                                   3 + 3                                        3 (13.6)
                                                   3 + 4                                        5 (22.7)
                                                   4 + 3                                        5 (22.7)
                                                   4 + 4                                        4 (18.2)
                                                   4 + 5                                        4 (18.2)
  Pathology stage                                  pT2a                                         3 (13.6)
                                                   pT2b                                         5 (22.7)
                                                   pT3a                                         7 (31.8)
                                                   pT3b                                         6 (27.3)
                                                   pT4                                          1 (4.5)
  Pathology Gleason score                          3 + 3                                        1 (4.5)
                                                   3 + 4                                        8 (36.4)
                                                   4 + 3                                        4 (18.2)
                                                   4 + 4                                        4 (18.2)
                                                   4 + 5                                        3 (13.6)
                                                   5 + 4                                        1 (4.5)
                                                   Not Graded[2](#T1FN2){ref-type="table-fn"}   1 (4.5)
  Prior radiation treatment                        EBRT                                         11 (50)
                                                   Untreated                                    11 (50)

Clinical stage was determined prior to primary or salvage surgery;

One index tumor was not graded due to treatment effect. EBRT: External beam radiation therapy.

Index tumor localization rates were 0.95 (95%CI: 0.77-1.00) for ^1^H-MRSI and 0.14 (95%CI: 0.03-0.35) for ^18^F-FDG-PET/CT, with 21 out of 22 index tumors found on pathology identified on ^1^H-MRSI and only 3 of those 21 index lesions identified on ^18^F-FDG-PET/CT. Figure [1](#F1){ref-type="fig"} shows ^1^H-MRSI, ^18^F-FDG-PET/CT and whole-mount step-section pathology from a patient in whom the tumor seen at pathology was observed by multimodality imaging. Figure [2](#F2){ref-type="fig"} shows ^1^H-MRSI, ^18^F-FDG-PET/CT and whole-mount step-section pathology from a patient in whom the tumor seen at pathology was observed by ^1^H-MRSI only. In the 3 patients with positive PET findings, the total tumor volumes measured by PET were 10.9, 11.1 and 10.4 cc and the SUVmax values were 3.3, 3.5 and 4.5. On ^1^H-MRSI in the 21 positive patients, CC/Cmax (median 6.4, range: 0.5-37.4), CC/Cmean (median 2.0, range: 0.5-18.5) and number of suspicious voxels (median 9.0, range 2-32) showed more profound alterations for all patients. Both the scatter plots (Figure [3](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}) and the Spearman rank correlations indicated little relationship between ^1^H-MRSI parameters and ^18^F-FDG-PET/CT. Spearman's ρ ranged between -0.362 and 0.28 (*P*-values range: 0.10-0.66). No clear pattern of association was detected in the graphs.

![Representative 1.5T magnetic resonance imaging/magnetic resonance spectroscopic imaging in a 58-year-old patient with prostate specific antigen 96.53 ng/mL, clinical stage T3 and surgical Gleason score 4 + 5. A: Axial T2-weighted image and overlaid point-resolved spectroscopic box indicating excitation region selected and 3D MRSI demonstrating three suspicious voxels marked with asterisks; B: ^18^F-FDG-PET/CT fusion image shows a focal uptake in the left prostate; C: Whole-mount step-section histopathology after radical prostatectomy shows a large cancer in the left prostate. MRSI: Magnetic resonance spectroscopic imaging; ^18^F-FDG-PET/CT: ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography.](WJR-9-134-g001){#F1}

###### 

Spearman correlations between proton magnetic resonance spectroscopic imaging and ^18^F-fluorodeoxyglucose data (*n* = 22)

  **[1](#T2FN1){ref-type="table-fn"}H-MRSI**   **[18](#T2FN2){ref-type="table-fn"}F-FDG**   **Rho (ρ)**   ***P*-value**
  -------------------------------------------- -------------------------------------------- ------------- ---------------
  CC/Cmax                                      SUVmax                                       -0.281        0.21
                                               SUVmean                                      -0.101        0.66
  CC/Cmean                                     SUVmax                                       -0.362        0.10
                                               SUVmean                                      -0.158        0.48
  Total \# Voxels                              SUVmax                                       0.2565        0.25
                                               SUVmean                                      0.2783        0.21

H-MRSI: Proton magnetic resonance spectroscopic imaging;

F-FDG: ^18^F-fluorodeoxyglucose.

![Representative 1.5T magnetic resonance imaging/magnetic resonance spectroscopic imaging in a 64-year-old patient with prostate specific antigen 4.9 ng/mL, clinical stage T3 and surgical Gleason score 4 + 3. A: Axial T2-weighted image and overlaid point-resolved spectroscopic box indicating excitation region selected and 3D MRSI demonstrating ten suspicious voxels marked with asterisks; B: ^18^F-FDG-PET/CT fusion image shows no focal uptake in the prostate; C: Whole-mount step-section histopathology after radical prostatectomy shows a large cancer extending from medial to right side of the prostate. MRSI: Magnetic resonance spectroscopic imaging; ^18^F-FDG-PET/CT: ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography.](WJR-9-134-g002){#F2}

![Scatter plots demonstrating the relationships between proton magnetic resonance spectroscopic imaging and ^18^F-fluorodeoxyglucose positron emission tomography parameters (*n* = 22). PET: Positron emission tomography.](WJR-9-134-g003){#F3}

Gleason scores ranged from 6 (8/22, 36%) to 9 (4/22, 18.1%) with one patient lacking a score due to treatment effect. This patient was excluded from further analysis. Both the total number of voxels (ρ = 0.55, *P* = 0.0099) and the SUVmax (ρ = 0.46, *P* = 0.0366) correlated with the Gleason score. No significant relationship was found between the CC/Cmax, CC/Cmean or SUVmean and the Gleason score (*P* = 0.15-0.79, Table [3](#T3){ref-type="table"}). The box plots demonstrate an upward trend for total number of voxels and SUVmax with each subsequent Gleason score (Figure [4](#F4){ref-type="fig"}).

###### 

Spearman correlations between proton magnetic resonance spectroscopic imaging and ^18^F-fluorodeoxyglucose data and surgical Gleason score (*n* = 22)

                    **With Gleason score**   
  ----------------- ------------------------ --------
  CC/Cmax           0.2165                   0.35
  CC/Cmean          0.0624                   0.79
  Total \# Voxels   0.5493                   0.0099
  SUVmean           0.3225                   0.15
  SUVmax            0.4584                   0.0366

H-MRSI: Proton magnetic resonance spectroscopic imaging;

F-FDG: ^18^F-fluorodeoxyglucose.

![Box plots demonstrating the relationships between surgical Gleason score and imaging parameters (*n* = 22).](WJR-9-134-g004){#F4}

DISCUSSION
==========

Multimodality imaging in PCa detection on ^1^H-MRSI is based on the detection of decreased citrate and polyamines with elevated choline\[[@B2],[@B4]\]. This is reflected in the high CC/Cmax (median 9.0) and CC/Cmean (median: 2.0) for the prostate index lesions. On ^18^F-FDG-PET/CT, PCa is identified based on increased glucose uptake by glucose transporters (GLUT) and glucose phosphorylation to glucose-6-phosphate by hexokinase\[[@B3],[@B8]\]. The present study adds to the literature for patients with local or loco-regional primary or recurrent PCa and shows that the citrate decrease in PCa was both much more frequent and pronounced than was the elevation in ^18^F-FDG uptake. This is in-line with the known low sensitivity of ^18^F-FDG-PET/CT for detecting localized primary PCa. Further research is needed to develop a clearer understanding of the underlying genomic and metabolic mechanisms and to confirm whether metabolic alterations progress stepwise from early abnormalities in citrate metabolism to late abnormalities in glucose metabolism. Since our patients were imaged at only one time point, the data appear consistent with this understanding. Improved understanding of PCa metabolism could help in determining the most appropriate imaging modalities (including imaging with radiotracers) for different clinical stages of PCa and possibly also in identifying and monitoring novel targeted therapies.

For instance, according to the "bioenergetic theory of prostate malignancy"\[[@B1],[@B17]\], the normal prostate produces and secretes an enormous amount of citrate; this is achieved by zinc-induced inhibition of m-aconitase, a Krebs cycle enzyme that converts citrate to isocitrate. With this truncated Krebs cycle, the normal prostate sacrifices ATP production for citrate secretion\[[@B17]\]. Conversely, in PCa, down-regulation of multiple membrane zinc transporters and zinc decline lead to activation of the full Krebs cycle, oxidation and a consequent decrease in intracellular and secreted citrate and increase in ATP production supporting malignancy\[[@B30]-[@B32]\]. However, the decline of citrate in PCa could also be related to its conversion to AcCoA by cytosolic ATP citrate lyase (ACLY) and subsequent utilization for fatty acid synthesis\[[@B30],[@B33],[@B34]\]. Activation of ACLY seems to be critical for biosynthesis and growth in various cancer models\[[@B30],[@B34]\]. Thus, based on this bioenergetic theory, two possible scenarios could explain the low ^18^F-FDG uptake in early, slow-growing PCa: (1) early PCa exhibits only a mildly increased cellular energy demand that is matched by activation of the mitochondrial Krebs cycle (bioenergetic mode); or (2) early PCa exhibits an unchanged energy demand and retains a persistently truncated Krebs cycle, but it diverts cytosolic citrate from secretion to fatty acid synthesis (biosynthetic mode*)*.

Biochemical alterations in PCa may be linked to signaling pathways implicated in PCa initiation and progression. For example, the PTEN/PI-3-Kinase pathway, one of the central pathways in early PCa, is closely linked to cellular metabolism\[[@B35]\]. PTEN tumor suppressor loss, with subsequent activation of the PI-3-Kinase pathway and downstream effectors such as AKT and mTOR\[[@B36],[@B37]\], has anabolic effects leading to increased glucose and amino acid uptake for the purposes of protein, fatty acid, and membrane synthesis, as well as the expression and membrane localization of glucose transporters\[[@B38]\]. Other consequences of PTEN loss include hexokinase translocation to the mitochondrial membrane\[[@B39]\], FA synthesis *via* ACLY\[[@B40],[@B41]\], steroid hormone-dependent FA synthesis\[[@B42]\], glycogen synthesis, membrane localization of amino-acid transporters, amino-acid uptake, and protein synthesis\[[@B43]\]. Other signaling alterations that typically occur later in PCa progression may also eventually upregulate glycolysis. Loss of p53, for example, is associated with increased glycolysis through GLUT3 expression\[[@B44]\]. We therefore summarize the following: In early PCa, citrate is diverted from secretion to AKT-dependent FA synthesis and/or to zinc-deficiency-induced oxidation in the Krebs cycle, leading to a decline in citrate signal on ^1^H-MRSI. While AKT-dependent stimulation of glycolysis alone is insufficient to produce a detectable increase in ^18^F-FDG uptake in PCa, the subsequent loss of p53 further promotes glycolysis, resulting in a detectable difference in ^18^F-FDG uptake between PCa and normal prostate tissue. We are hoping that future studies which include genomic and proteomic tissue analysis, may eventually link tumor biology and imaging in PCa. Such links have been made in other studies. For instance, the extent of changes in intermediary metabolism on ^1^H-MRSI has been shown to correlate with the Gleason grade\[[@B14]\]. Similarly, risk scoring based on metabolic changes on ^1^H-MRSI has been found to correlate with treatment outcome in patients with high-risk PCa who underwent neoadjuvant chemotherapy/hormone therapy before radical prostatectomy or radiation therapy\[[@B15]\]. Conversely, near-normal intermediary metabolism on pre-treatment ^1^H-MRSI has been found to predict very-low-risk PCa in radical prostatectomy specimens\[[@B16]\].

Certain PET tracers are superior to ^18^F-FDG in detecting early PCa and early recurrence after radical prostatectomy or radiation therapy\[[@B18]-[@B24]\]. In contrast, in the most-advanced form of PCa, castration-resistant disease, ^18^F-FDG-PET/CT is predictive of survival\[[@B28],[@B45]\], supporting the statement that increased glycolysis represents a late and ominous event in the progression of PCa. Of note, ^18^F-FDG-PET/CT has been established as predictive of outcome in multiple other cancers, with high ^18^F-FDG avidity predicting poor outcome\[[@B46]-[@B49]\]. The present study has a few limitations given its retrospective study design and the fact that we could not control for treatment. Also, due to a low sample size, it was not feasible to estimate survival. However, this study met its purpose of exploring the relationship using multimodality imaging between ^1^H-MRSI and ^18^F-FDG-PET/CT in PCa patients. To optimize PCa multimodality imaging, it is critical to understand how different metabolic imaging techniques interact and how they can be used to develop the most effective imaging protocols.

The present study suggests that the concentration of intermediary metabolites detected by ^1^H MRSI and glycolytic flux measured ^18^F-FDG PET show little correlation. Furthermore, only few tumors were FDG avid on PET, possibly because increased glycolysis represents a late and rather ominous event in the progression of PCa.
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Background
----------

Although metabolic imaging is increasingly utilized in prostate cancer (PCa), the mechanisms leading to cancer-related metabolic rearrangements and consequent imaging findings remain poorly understood. The aim of the study was to better understand the sequence of metabolic changes in localized PCa.

Research frontiers
------------------

To optimize PCa multimodality imaging, it is critical to understand how different metabolic imaging techniques interact and how they can be used to develop the most effective imaging protocols.

Innovations and breakthroughs
-----------------------------

Comparison of proton magnetic resonance spectroscopic imaging (^1^H-MRSI) and ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG-PET/CT) findings in local PCa demonstrated that abnormal choline intermediary metabolism on ^1^H-MRSI precedes the changes in glycolysis on ^18^F-FDG-PET/CT.

Applications
------------

In principle, imaging analysis of distinct metabolic pathways in PCa can be utilized to predict patient outcome, optimize management, and plan future diagnostic and therapeutic trials in PCa.

Terminology
-----------

^1^H-MRSI: Proton magnetic resonance spectroscopic imaging; ^18^F-FDG-PET: ^18^F-FDG-positron emission tomography; PCa: Prostate cancer.
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